title: [Role of bosentan in patients with chronic venous thromboembolic pulmonary hypertension].
abstract: OBJECTIVE
  Chronic thromboembolic pulmonary hypertension (CTEPH) has a dismal prognosis when there are no central pulmonary thrombi amenable to surgical thromboendarterectomy. Pulmonary vasodilators could be useful in this setting. Initial experience with bosentan in a small group of patients with CTEPH has shown favourable results on the short term (3 to 6 months), but long-term effects remain unknown.
  
  
  METHODS
  We retrospectively describe the effects of bosentan in 6 CTEPH patients with a mean follow-up period of 15 months (range, 8-26).
  
  
  RESULTS
  At 3-month follow-up, all patients had experienced clinical improvement, with a statistical trend towards reduced pulmonary vascular resistance [1,008 (624) dyn/sec/cm-5 versus 768 (392), p = 0.07]. Clinical improvement persisted on the long-term, [baseline NYHA functional class 3.0 (0.4) versus 2.0 (0) at the last follow-up visit, p < 0.01]. Six-minute walk-test results [baseline 230 (124) meters versus a 313 (70) at 1 year] and NTproBNP [2,225 (2,079) pg/ml versus a 1,056 (1,104) at 1 year] were also consistent with persistent beneficial effect.
  
  
  CONCLUSIONS
  Bosentan seemed to provide long-term benefits in this small series of patients with CTEPH.
authors.affiliation: Unidad de Trasplante Cardíaco e Hipertensión Pulmonar, Hospital Universitario Puerta de Hierro, San Martín de Porres 4, 28035 Madrid, Spain. jsecu@telefonica.net
authors.forename: Javier
authors.initials: J
authors.lastname: Segovia Cubero
authors.forename: Juan Camilo
authors.initials: JC
authors.lastname: Ortiz Uribe
authors.forename: Manuel
authors.initials: M
authors.lastname: Gómez Bueno
authors.forename: Vanessa
authors.initials: V
authors.lastname: Moñivas Palomero
authors.forename: Magdalena
authors.initials: M
authors.lastname: González González
authors.forename: Luis
authors.initials: L
authors.lastname: Alonso-Pulpón Rivera
mesh_terms: D000284:Administration, Oral; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077300:Bosentan; D002908:Chronic Disease; D003627:Data Interpretation, Statistical; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000188:drug therapy*; D012189:Retrospective Studies; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D013449:Sulfonamides; D000077300:Bosentan